Posts

After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing

on
Rallybio and Avenzo Therapeutics announced a merger agreement on June 1, 2026, under which Rallybio will acquire Avenzo; the combined company will operate as Avenzo Therapeutics and trade on Nasdaq under the ticker AVZO; Rallybio’s assets and legacy business will be largely divested, while Avenzo brings next‑generation oncology programs and a $215 million financing. Sources: RallyBio tries again for reverse merger, this time with Avenzo Avenzo Therapeutics to be Acquired by Rallybio - Cooley Candid scores Nasdaq listing via reverse merger Rallybio doc-inhzzcpm4504994.shtml.md Avenzo反向收购Rallybio！核心资产源于中国 - 新浪财经 Rallybio The M&A Hunter (@maandhunter): "RLYB | Rallybio - Substack EX-99.1 - SEC.gov Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

AstraZeneca's triplet combo (Imfinzi/Imjudo/lenvatinib) plus TACE helps a subset of liver cancer patients avoid progression

on

ASCO26: With daraxonrasib in the spotlight, Immuneering makes case for its drug in 1L pancreatic cancer

on

Laverock Therapeutics Awarded Over £2.2M in Innovation Grants for AI‑Powered Platform and Non‑Oncology Expansion

on

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

on

Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback

on

ASCO 2026: Lilly’s Retevmo tied to dramatic outcomes in early‑stage RET fusion‑positive lung cancer

on

ASCO 2026: J&J shows Erleada can break prostate cancer treatment mold in high‑risk localized disease

on

Shionogi's COVID Antiviral Xocova Approved by FDA as Post‑Exposure Preventive for COVID-19 in the U.S.

on

Servier inks up to $2.65B buyout of Edgewise's muscular dystrophy unit to boost neurology pipeline

on

Lilly signs up to $1.26B deal for Hanmi's GLP‑2 drug sonefpeglutide for short bowel syndrome and other indications

on

ASCO 2026: A battle of bispecifics, Eli Lilly’s big win and more

on

Kelonia Therapeutics delivers impressive in vivo CAR-T update

on